country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-124584A

Copy Link Print Information

Minnelide free base

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Minnelide free base is a prodrug of Triptolide (HY-32735) that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide free base promotes apoptosis.

For research use only. We do not sell to patients.

CAS No.: 1254885-39-6
Formula: C₂₁H₂₇O₁₀P
Molecular Weight:470.41

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (280 KB)

Minnelide free base Chemical Structure

CAS No.: 1254885-39-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

Minnelide (0-200 nM; 48 hours) free base shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) free base leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors^[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) free base prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells^[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) free base causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1254885-39-6
Molecular Weight 470.41
Formula C₂₁H₂₇O₁₀P
SMILES

C[C@@]12[C@@]34[C@]([C@@H]5C[C@@]1([H])C6=C(C(OC6)=O)CC2)(O5)[C@@H]([C@](O7)(C(C)C)[C@@H]7[C@@H]3O4)OCOP(O)(O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (3)

All Cell Proliferation/Viability AssayApoptosis AnalysisWBIn Vivo Efficacy StudyIn Vivo Imaging

Sort by:

Journal Impact Factor

J Clin Invest

Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase-initiated genetically engineered mouse model. [Abstract]

2026 Jun 16:e202218. PMID: 42302177
Phytomedicine

Minnelide exhibits antileukemic activity by targeting the Ars2/miR-190a-3p axis. [Abstract]

2024 May 11:130:155724. PMID: 38759317
Res Sq

Dual activity of Minnelide chemosensitize basal/triple negative breast cancer stem cells and reprograms immunosuppressive tumor microenvironment. [Abstract]

2024 Feb 22:rs.3.rs-3959342. PMID: 38464167

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Human breast cancer cell lines, MDA-MB231, Sum159, ZR75–1, MCF7 AND murine breast cancer cell lines, EMT6, E00771, AT3 and 4T1 were incubated with indicated doses of Minnelide (0, 25, 50, 75, 100 μM) for 48 hours and cell viability was measured by MTT assay.

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Breast cancer cell lines, MDA-MB-231 and MCF7 were incubated with indicated doses of Minnelide (0, 25, 50, 75 μM) for 48 hours and apoptotic cell death and CSC population was evaluated by flow cytometer.

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Protein expression of HSP70/72, A20, Vimentin, MYC and BRD4 was shown in human MDA-MB-231 and murine 4T1 and EMT6 cell lines treated with increased dose of Minnelide in the presence and absence of recombinant human TGFβ.

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Size of primary tumors and their weights at the end point of the experiment treated with single Minnelide (0.5 mg/kg).

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Minnelide (0.5 mg/kg) alone significantly reduced the relapse after surgery, and it eliminated all residual tumors when combined with CTX. D. Survival rates of 4T1 tumor bearing mice before and after the resections.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Noel P, et al. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327-341. [Content Brief]

[2]. Chugh R, et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Minnelide free base

3 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Purity & Documentation
References

1/16
1/16

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Customer Validation
Human breast cancer cell lines, MDA-MB231, Sum159, ZR75–1, MCF7 AND murine breast cancer cell lines, EMT6, E00771, AT3 and 4T1 were incubated with indicated doses of Minnelide (0, 25, 50, 75, 100 μM) for 48 hours and cell viability was measured by MTT assay.
1/16

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Customer Validation
Breast cancer cell lines, MDA-MB-231 and MCF7 were incubated with indicated doses of Minnelide (0, 25, 50, 75 μM) for 48 hours and apoptotic cell death and CSC population was evaluated by flow cytometer.
1/16

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Customer Validation
Protein expression of HSP70/72, A20, Vimentin, MYC and BRD4 was shown in human MDA-MB-231 and murine 4T1 and EMT6 cell lines treated with increased dose of Minnelide in the presence and absence of recombinant human TGFβ.
1/16

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Customer Validation
Size of primary tumors and their weights at the end point of the experiment treated with single Minnelide (0.5 mg/kg).
1/16

Minnelide free base purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Customer Validation
Minnelide (0.5 mg/kg) alone significantly reduced the relapse after surgery, and it eliminated all residual tumors when combined with CTX. D. Survival rates of 4T1 tumor bearing mice before and after the resections.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Minnelide free base

Publications Citing Use of MedChemExpress (MCE) Minnelide free base

Biological Activity

Chemical Information

Publications (3)

Purity & Documentation

References

Calculators

Help & FAQs

Minnelide free base Related Classifications

HY-124584A Related Classifications